Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
ELA026 has the potential to address a high unmet need for patients with a rare, life-threatening hyperinflammatory disease SOUTH SAN FRANCISCO, CA, October 30, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) […]
